BioLineRx Ltd. (BLRX) Form 6-K — Oct 23, 2026
BioLineRx and partner Hemispherian presented preclinical data at ESMO 2026 showing GLIX1 synergizes with PARP inhibitors (olaparib, veliparib, niraparib) in HR-proficient ovarian cancer cell lines, with ZIP synergy scores from 10.9 to 43.2. In an in vivo patient-derived xenograft model, a low-dose GLIX1 plus olaparib combination showed statistically significant tumor growth inhibition versus vehicle control, and activity comparable to cisplatin, outperforming either agent alone at optimal doses.
Key figures
- Glix1 dose pdx
- 50 mg/kg daily in combination
- Olaparib dose pdx
- 10 mg/kg daily in combination
- Zip synergy scores
- 10.9 to 43.2 (olaparib: 15.4-43.0; veliparib: 10.9-43.2; niraparib: 12.2-39.8)
- Tumor to plasma ratio
- approximately 50%
- Ovarian cancer deaths 2026
- over 12,000
- Ovarian cancer new cases 2026
- estimated 21,000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.